Dolutegravir demonstrated noninferiority to low-dose efavirenz in antiretroviral (ART)-naïve patients with HIV-1 infection in a resource-limited setting, according to the NAMSAL ANRS 12313* study presented at IAS 2019.
Vocinti® (vonoprazan), a first-in-class potassium-competitive acid blocker (P-CAB) is now available in Malaysia for use in Helicobacter pylori eradication therapy and erosive (reflux) oesophagitis treatment.
A phase II randomized, controlled trial has recently reaffirmed the safety profile of ceftazidime–avibactam in children with complicated urinary tract infection (cUTI), which is consistent with that of adults and of ceftazidime monotherapy.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.
Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.
The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.
Besifovir dipivoxil maleate has antiviral efficacy against chronic hepatitis B that is similar to that of tenofovir disoproxil fumarate but with a lower impact on bone and renal safety, as shown in the results of a phase III trial involving Asian patients.
The investigational first-in-class attachment inhibitor prodrug fostemsavir (FTR) continues to improve virologic and immunologic response from weeks 48 to 96 in patients with multidrug-resistant HIV-1 who had been heavily treated, according to the BRIGHTE* study presented at IAS 2019.
Individuals with HIV-1 who demonstrate virologic suppression on a tenofovir alafenamide fumarate (TAF)-based three- or four-drug regimen (TBR) could safely switch to a two-drug regimen comprising dolutegravir and lamivudine, according to results from the phase III TANGO* study presented at the recent International AIDS Society conference (IAS 2019).
There is a steady annual growth in the incidence rate of syphilis in men living with HIV, according to a new Singapore study. Rates are consistently higher among men who have sex with men (MSM) than their heterosexual counterparts.
Individuals with obesity are at an elevated risk of developing infections, particularly that of the skin in both men and women, and those of the gastrointestinal and urinary tracts and sepsis in women only, according to a study.
An increase in intensive care unit (ICU) management and bacterial pneumonia development occurs in children with special risk medical conditions (SRMC), but a rise in the probability of death or need for mechanical ventilation remains inconsistent, suggests a recent study.
Oral amoxicillin–clavulanate effectively promotes resolution of nonsevere acute exacerbations in children with non-cystic
fibrosis (CF) bronchiectasis, thus confirming the role of amoxicillin–clavulanate as first-line treatment for bronchiectasis, according to results from the three-arm BEST-1 study.